Join us at Curecast
On November 6, Katie Couric, leading experts, and advocates will share how Project Cure CRC is transforming research and advancing care.
What is tumor mutation burden (TMB)?
Tumor mutation burden (TMB) is a measure of the number of mutations carried by tumor cells. Tumors with many mutations have a high mutation burden (high TMB).
Many tumors with a high TMB (equal to or greater than 10) also have the biomarker MSI-H.
In MSI-H tumors, the somatic mutation occurs in one of the DNA mismatch repair genes that also results in MSI-H. These mutations can be passed along to new tumor cells during cell division. A small percentage of tumors with TMB also have the biomarker MSS.
What happens if I have a high TMB?
Knowing the TMB score of a tumor may help predict how well it will respond to immunotherapies.
This can help you and your doctor find the right treatment plan for you.
Related Topics
Other biomarkers
UGT1A1 BiomarkerTop resources
2025 ASCO update: Six big studies
The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.
Last updated
Hope in the Details: How Heather’s Biomarker Opened New Treatment Paths
After a stage IV colorectal cancer diagnosis, Heather’s biomarker test revealed a critical mutation — opening the door to clinical trials and new hope.
Last updated
Lexie Haglund: Beating stage IV CRC
Discover how knowing her G12C biomarker guided Lexie’s stage IV colorectal cancer treatment — from a shock diagnosis to HIPEC surgery — and why screening, research, and self-advocacy matter.
Last updated